Oncoceutics

81 articles about Oncoceutics

• Oncoceutics Invited to Present ONC201 at Public Advisory Committee Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019

  5/7/2019

  Oncoceutics announced that the US Food and Drug Administration invited the company to present information regarding its lead compound ONC201 at the public advisory committee meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019.  

• Research Publications Demonstrate Imipridones Target Mitochondrial Function in Cancer Cells

  5/3/2019

  In AML, ClpP is over-expressed in patient samples and its hyperactivation selectively kills cancer cells independent of p53 status, while not affecting normal cells.

• Composition of Matter Patent and Translational Research Grant issued for ONC213

  4/30/2019

  Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,266,533 entitled “7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO [3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY” with an expiration date of January 29, 2036.

• ABC2 Awards Grant to Develop Natural Disease History Benchmark for the Development of ONC201 in Midline Gliomas

  4/24/2019

  Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant to a research team at University of California, Los Angeles to perform a natural disease history study of adult midline gliomas, a certain type of aggressive brain tumors.

• Case Report in the Journal of Neurosurgery Highlights Potential of ONC201 in H3 K27M-mutant DIPG

  4/10/2019

  Oncoceutics announced today the publication of an article entitled "First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report” in the Journal of Neurosurgery (authored by Matthew D. Hall, M.D., MBA).

• Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe

  3/25/2019

  Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.

• Oncoceutics and the National Cancer Institute Collaborate to Develop ONC206

  3/20/2019

  Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds

• xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

  3/12/2019

  xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201.

• Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd.

  2/15/2019

  In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories. 

• Oncoceutics Expands Patent Family to Include Use of ONC201 in H3 K27M-Mutant Gliomas

  1/14/2019

  Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a Histone 3 K27M (H3 K27M) mutation

• Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors

  7/31/2018

  Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology.

• Oncoceutics and Calvert Research Announce Development/Investment Agreement for ONC 206

  2/15/2018

  Oncoceutics and Calvert Research, LLC announced that the two companies have entered into a second product development and investment partnership agreement, this time to further develop and enable the submission of an IND application for ONC206, Oncoceutics' next generation molecule.  

• Oncoceutics Announces Appointment of Dr. Minesh Mehta to the Board of Directors

  2/12/2018

  Oncoceutics announced the appointment of Minesh Mehta, MD, FASTRO, to the company’s Board of Directors.

• Oncoceutics Release: ONC201 Trial Begins at NYU for Children With H3 K27M Mutant Glioma

  1/31/2018

  Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.

• Oncoceutics and Frontida BioPharm Announce Product Development and Commercialization Partnership

  1/16/2018

  Oncoceutics and Frontida BioPharm announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201,

• Oncoceutics Extends IP Coverage to Japan With New Patent Covering All Cancers

  1/9/2018

  Oncoceutics announced that the Japanese Patent Office has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers, and glioblastoma. 

• Oncoceutics Extends Composition of Matter Patent Portfolio to ONC212

  12/20/2017

  Oncoceutics announced that the USPTO issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics' lead compound ONC201.

• Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

  11/13/2017

  Oncoceutics today announced that five clinical and preclinical presentations on ONC201 and ONC206 for the treatment of high grade gliomas will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology, held November 16th-19th in San Francisco.

• Oncoceutics Release: ONC201 Trial for Histone Mutant Glioma Begins at NYU

  11/7/2017

  Oncoceutics announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent high-grade gliomas that contain a specific mutation called the histone H3 K27M mutation.

• Oncoceutics And MD Anderson Cancer Center Expand Alliance To Cover Imipridone ONC212

  10/10/2017